Λεξικό .. Alutard SQ (ALK-Abelló)

Alutard SQ (ALK-Abelló).  Alutard SQ® is a purified, qualitatively and quantitatively standardised allergen product in a sustained-release formulation for subcutaneous injection. Active substance: Allergen extract expressed in SQ units. Excipients: Aluminum hydroxide, phenol, sodium chloride, sodium hydrogen carbonate and water for injection. Uses: Allergic rhinoconjunctivitis and mild to moderate allergic asthma. Contraindications/warnings: Immunological diseases (e.g. immune complex and immuno-deficiency diseases), chronic lung/heart diseases, renal dysfunction and treatment with beta-blockers. Patients must be under observation for at least 30 minutes after each injection. Pregnancy: Treatment should not be initiated during pregnancy. Side effects: The possibility of local or systemic allergic reactions must always be considered with allergen injections. Pack sizes: Initial therapy: Vials 1, 2, 3 and 4, each containing 5 ml. Maintenance therapy: 1 x vial 4 containing 5 ml or 2 x vial 4, each containing 5 ml. Available on prescription only. Pharmaceutical precautions: Must be stored at 2-8° C. Note: Prescribing information may vary from country to country. Further information can be obtained from either the local ALK-Abelló company or: ALK-Abelló A/S, Bøge Allé 6-8, DK-2970 Hørsholm, Denmark.

Treatment with Alutard SQ significantly improved the seasonal QoL of patients suffering from allergic rhinoconjunctivitis. The improvement was more pronounced and wider ranging in patients who received the higher 100,000 SQ-U maintenance dose [1].

Treatment with Alutard SQ significantly improved the seasonal QoL of patients suffering from allergic rhinoconjunctivitis. The improvement was more pronounced and wider ranging in patients who received the higher 100,000 SQ-U maintenance dose [2].

Francis JN, et al (2008) investigated the relationship between clinical responsiveness, regulatory cytokine production, and antibody responses to allergen during 1 year of immunotherapy administering an alum-adsorbed grass pollen vaccine (Alutard SQ) in  eighteen patients  with severe seasonal allergic rhinitis who were randomized double-blind to receive active or placebo injections of. IL-10 responses occur early but at immunotherapy doses that were  not clinically effective. Later induction of inhibitory antibodies, including IgG4 and IgA, might be required for efficacy through modulation of IgE-mediated events [3].

References

1. Powell RJ, Frew AJ, Corrigan CJ, Durham SR. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy. 2007 Nov;62(11):1335-8. Epub 2007 Aug 21.

3. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, Till SJ. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008 May;121(5):1120-1125.e2. Epub 2008 Apr 18.